Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes.
Sundar R, Chia DKA, Zhao JJ, Lee ARYB, Kim G, Tan HL, Pang A, Shabbir A, Willaert W, Ma H, Huang KK, Hagihara T, Tan ALK, Ong CJ, Wong JSM, Seo CJ, Walsh R, Chan G, Cheo SW, Soh CCC, Callebout E, Geboes K, Ng MCH, Lum JHY, Leow WQ, Selvarajan S, Hoorens A, Ang WH, Pang H, Tan P, Yong WP, Chia CSL, Ceelen W, So JBY. Sundar R, et al. Among authors: ng mch. ESMO Open. 2024 Sep;9(9):103681. doi: 10.1016/j.esmoop.2024.103681. Epub 2024 Sep 16. ESMO Open. 2024. PMID: 39288528 Free PMC article. Clinical Trial.
Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases.
Zhao JJ, Ong CJ, Srivastava S, Chia DKA, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay ST, Hagihara T, Tan ALK, Teo MCC, Tan QX, Ng G, Tan JW, Ng MCH, Gwee YX, Walsh R, Law JH, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh BT, Hong JH, Tay RYK, Teo CB, Dings MPG, Bijlsma M, Lum JHY, Mathur S, Pietrantonio F, Blum SM, van Laarhoven H, Klempner SJ, Yong WP, So JBY, Chen Q, Tan P, Sundar R. Zhao JJ, et al. Among authors: ng mch. Gastroenterology. 2024 Aug 13:S0016-5085(24)05348-4. doi: 10.1053/j.gastro.2024.08.007. Online ahead of print. Gastroenterology. 2024. PMID: 39147169 Free article.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Grivas P, Garralda E, Meric-Bernstam F, Mellinghoff IK, Goyal L, Harding JJ, Dees EC, Bahleda R, Azad NS, Karippot A, Kurzrock R, Tabernero J, Kononen J, Ng MCH, Mehta R, Uboha NV, Bigot F, Boni V, Bowyer SE, Breder V, Cervantes A, Chan N, Cleary JM, Dhawan M, Eefsen RL, Ewing J, Graham DM, Guren TK, Won Kim J, Koynov K, Oh DY, Redman R, Yen CJ, Spetzler D, Roubaudi-Fraschini MC, Nicolas-Metral V, Ait-Sarkouh R, Zanna C, Ennaji A, Pokorska-Bocci A, Flaherty KT. Grivas P, et al. Among authors: ng mch. Clin Cancer Res. 2024 Oct 15;30(20):4572-4583. doi: 10.1158/1078-0432.CCR-24-0012. Clin Cancer Res. 2024. PMID: 38771739 Clinical Trial.
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP, Thura M, Gupta A, Tan SH, Kuan KKY, Ang KH, Merchant K, Chang KTE, Yon HY, Chen Y, Cheng MHW, Mahadev A, Ng MCH, Seng MS, Iyer P, Chia PL, Soh SY, Zeng Q. Loh AHP, et al. Among authors: ng mch. Mol Ther Oncolytics. 2023 Aug 18;30:153-166. doi: 10.1016/j.omto.2023.08.006. eCollection 2023 Sep 21. Mol Ther Oncolytics. 2023. PMID: 37674627 Free PMC article.
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.
Ho J, Heong V, Peng Yong W, Soo R, Ean Chee C, Wong A, Sundar R, Liang Thian Y, Gopinathan A, Yan Pang M, Koe P, Nathan Jeraj S, Pyar Soe P, Yar Soe M, Tang T, Ng MCH, Tai DWM, Tan TJY, Xu H, Chang H, Landesman Y, Shah J, Shacham S, Chin Lee S, Tan DSW, Cher Goh B, Tan DSP. Ho J, et al. Among authors: ng mch. Ther Adv Med Oncol. 2022 Apr 11;14:17588359221087555. doi: 10.1177/17588359221087555. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35432603 Free PMC article.
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Among authors: ng mch. Nat Commun. 2021 Nov 2;12(1):6431. doi: 10.1038/s41467-021-26548-6. Nat Commun. 2021. PMID: 34728638 Free PMC article. No abstract available.
27 results